Skip to content

Effect of vaginal probiotic on bacterial vaginosis and vaginal candidiasis

The effect of using vaginal probiotic supplementation on treatment results and vaginal colonization 2 and 6 month after treatment of bacterial vaginosis and Vulvovaginal Candidiasis

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
IRCT
Registry ID
IRCT2014050617603N1
Enrollment
140
Registered
2014-06-22
Start date
2014-04-20
Completion date
Unknown
Last updated
2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Condition 1: vulvitis and vulvovaginal candida. Condition 2: bacterial vaginosise. Candidiasis of vulva and vagina inflammation of vagina and vulva

Interventions

Intervention 1: Vaginal probiotic capsules containing Lactobacillus rhamnosus 10 ^ 9 colony is known to be vaginally twice a day for seven days. Intervention 2: Vaginal placebo capsule form twice a da
Treatment - Drugs
Placebo
Vaginal probiotic capsules containing Lactobacillus rhamnosus 10 ^ 9 colony is known to be vaginally twice a day for seven days
Vaginal placebo capsule form twice a day for seven days

Sponsors

Vice chancellor for Research, Shiraz University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
18 Years to 45 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria : aged 18 to 40 years ; Married ; nonpregnant ; willing to participate in research ; suffering from bacterial vaginosis or Vulvovaginal Candidiasis (according to the criteria of Amsel and culture test fungi ) ; having menstrual natural ? nonsmokers ; not suffering from diseases such as liver disease heart , kidney, diabetes , Sbby system diseases , immune deficiency , sexually transmitted diseases, abnormal vaginal bleeding ; lack of non-use of broad-spectrum antibiotics , hormones ( such as birth control pills ) , alcohol , drugs anticoagulant and immunosuppressive drugs during the past month ; lack of sexual intercourse during the last 48 hours of non-use vaginal medicines within the last 48 hours last 48 hours ; lack of vaginal washings or not sensitive to clindamycin clotrimazole during pregnancy Exclusion Criteria : allergies symptoms, allergy to clindamycin or clotrimazole vaginal probiotic or placebo ; Getting pregnant

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Cultivated candida. Timepoint: 2-5 days after initial treatment,2-5 days after and one month after the use of probiotics or placebo. Method of measurement: Cultivate.;Amsel criteria. Timepoint: 5-2 days after initial treatment,2-5 days after and one month after the use of probiotics or placebo. Method of measurement: Discharge, vaginal PH measurements,Whiff test, see clue cells under the microscope.;Cultures of vaginal lactobacilli. Timepoint: 2-5days after initial treatment,2-5 days after and one month after the use of probiotics or placebo. Method of measurement: Cultures of vaginal lactobacilli.

Secondary

MeasureTime frame
Reacton to probiotics - clindamycin -clotrimazole. Timepoint: During the entire study. Method of measurement: The patient complained.

Countries

Iran (Islamic Republic of)

Contacts

Public Contactsara Azima

Fatemeh (PBUH) College of Nursing and Midwifery

hooshyar_s@sums.ac.irazimas@sums.ac.ir00

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026